Barinthus Biotherapeutics plc.
No SEC Form 4 filings for $BRNS in the last 30 days.
Barinthus Biotherapeutics plc. (BRNS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 brns-20260630xexx991.htm EX-99.1 Document Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments • Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing • Completed enrollment of 42 plann
Barinthus Biotherapeutics plc. (BRNS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001828185 00-0000000 NASDAQ 0001828185 2026-06-30 2026-06-30 0001828185 VACC:AmericanDepositarySharesMember 2026-06-30 2026-06-30 0001828185 us-gaap:CommonStockMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHA
Barinthus Biotherapeutics has announced the appointment of Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026. Swirsky will provide his services through Grand Strand BioAdvisors LLC, receiving a monthly fee as part of an arrangement to strengthen the company's financial leadership. Barinthus (BRNS) currently holds a Buy rating from analysts with a $7.00 price target, though TipRanks’ AI Analyst, Spark, rates it as Neutral due to weak financial performance and bearish technicals.
Over the past 7 days, alphai's AI scored 1 news story mentioning BRNS (Barinthus Biotherapeutics plc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BRNS coverage spans financial news, earnings and corporate actions.
Near-term catalyst is AVALON MAD topline timing in Q4 2026, alongside Nasdaq bid-price compliance extension and progress toward the Clywedog merger.
The filing is primarily governance/administrative, but it reiterates a time-bound Nasdaq compliance risk (bid price) that can drive volatility.
The appointment of Douglas Swirsky as CFO may positively influence Barinthus Biotherapeutics' financial management, potentially supporting improved financial performance.
BRNS may experience minor investor attention due to its mention but is unlikely to be significantly affected.
Investigation news regarding Barinthus Biotherapeutics plc may introduce short-term volatility but is unlikely to cause long-term price disruption.
alphai scores every news story that mentions BRNS with an AI model for sentiment and relevance, and aggregates insider trades from Barinthus Biotherapeutics plc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Barinthus Biotherapeutics plc. (BRNS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 brns-20260630xexx991.htm EX-99.1 Document Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments • Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing • Completed enrollment of 42 plann
5 min readBarinthus Biotherapeutics plc. (BRNS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001828185 00-0000000 NASDAQ 0001828185 2026-06-30 2026-06-30 0001828185 VACC:AmericanDepositarySharesMember 2026-06-30 2026-06-30 0001828185 us-gaap:CommonStockMember 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHA
4 min readBarinthus Biotherapeutics has announced the appointment of Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026. Swirsky will provide his services through Grand Strand BioAdvisors LLC, receiving a monthly fee as part of an arrangement to strengthen the company's financial leadership. Barinthus (BRNS) currently holds a Buy rating from analysts with a $7.00 price target, though TipRanks’ AI Analyst, Spark, rates it as Neutral due to weak financial performance and bearish technicals.
3 min readNEW YORK, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
2 min readBALA CYNWYD, Pa., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
2 min readNEW YORK, Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
2 min readBALA CYNWYD, Pa., Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
3 min readGERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- GERMANTOWN, MD and ALTRINCHAM, UK - September 30, 2025 - Barinthus Biotherapeutics plc ( NASDAQ: BRNS ) ( "Barinthus Bio" ) , an immunology and inflammation company focused on developing therapies that promote immune ...
2 min read
